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Summary. We examined the feasibility of achieving a rapid
response in patients with previously untreated multiple
myeloma by administering vincristine 0·4 mg and doxo-
rubicin 9 mg/m2 as a rapid intravenous infusion for 4 d
together with intermittent high-dose dexamethasone 40 mg
(VAD) for remission induction treatment in patients who
were scheduled to receive high-dose therapy. 139 patients
(86 male, 53 female; median age 53 years, range 32–65
years; Durie & Salmon stage IIA: 42, IIB: one, IIIA: 89,
IIIB: seven) were included in a prospective multicentre
study in which VAD was administered as remission
induction treatment and was followed by intensified
treatment. The response was evaluated according to the
criteria of the Eastern Cooperative Oncology Group (ECOG).
The results of treatment were evaluable in 134 patients.
Five patients died before evaluation. 86 patients (62%)
achieved a partial response (PR) and seven patients (5%)
achieved a complete response (CR), which equates to a
response rate of 67%. The main side-effect was mild
neurotoxicity, which was observed in 18% of the patients.
Fever or infections were reported in 27% of the patients. VAD
administered as an outpatient regimen, based on rapid
intravenous infusion, is an effective induction regimen for
untreated myeloma with a 67% response rate and acceptable
toxicity.
Keywords: multiple myeloma, induction treatment, chemo-
therapy, VAD, rapid infusion.
With the introduction of melphalan and prednisolone as
remission induction therapy the median survival of patients
with multiple myeloma improved from 17 months to 30–36
months (Gregory et al, 1992). Since then, several combina-
tion chemotherapy regimens have been used in an attempt
to improve the survival and response rate in newly diagnosed
patients with multiple myeloma which did not show super-
iority over melphalan and prednisolone (Gregory et al,
1992). The combination of vincristine and doxorubicin
administered as a continuous infusion together with
intermittent high-dose dexamethasone (VAD), a non-alky-
lating agent-based regimen, induces rapid and marked
responses in newly diagnosed patients and in patients with
relapsed or refractory myeloma (Alexanian et al, 1990;
Barlogie et al, 1984). Usually vincristine and doxorubicin in
this regimen are administered by a continuous infusion via
an indwelling catheter, which imposes logistic problems for
outpatient administration. We now report the feasibility of
administering VAD as an outpatient schedule using 4 d of
rapid intravenous infusion in patients with previously
untreated multiple myeloma. This regimen was designed in
order to investigate the feasibility of achieving a rapid
response with outpatient treatment in newly diagnosed
patients, while conserving the well-proven efficacy of
continuous infusional VAD. In this study only patients <66
years of age were included who were scheduled to receive
further intensified treatment. No elderly patients were
studied.
METHODS
Study design. From December 1995 to April 1998, 232
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patients aged 15–65 years with previously untreated
multiple myeloma were registered in a prospective multi-
centre study for intensified treatment following remission
induction treatment. In this study three or four cycles of
rapid intravenous VAD were given as standard remission
induction treatment to all patients. Thereafter patients were
randomized to receive either intensified treatment including
peripheral blood stem cell transplantation followed by
interferon-a maintenance or intensive chemotherapy with-
out stem cell support followed by interferon-a maintenance.
Patients with multiple myeloma stage II or III and younger
than 66 years of age were included in the study. Patients
with World Health Organization (W.H.O.) performance
status of 4 and patients with concomitant severe cardiac,
pulmonary, neurologic or metabolic disease were excluded
from registration.
Patient characteristics. 139 patients (86 male and 53
female) who had at least 1 year of follow-up after VAD were
included in this analysis. All patients received rapid
intravenous infusion of VAD as remission induction regimen
(Table I). All patients gave written informed consent. The
study was performed according to the Helsinki agreement.
The median age of the patients was 53 years, ranging
from 32 to 65 years. According to the Salmon & Durie
classification, 42 patients had stage IIA disease and 89
patients had stage IIIA disease, one patient had stage
IIB and seven patients had stage IIIB disease (Durie &
Salmon, 1975). 40 patients had IgA, 73 patients IgG
and three patients had IgD myeloma. One patient had an IgM
M-component and 18 patients had urinary light chain
disease. Four patients had non-secretory myeloma.
Before the start of treatment with VAD, 46 patients had a
W.H.O. performance status of 0, 64 patients a status of 1, 17
patients a status of 2, and eight patients a status of 3. The
performance status before VAD was not known in four
patients.
Treatment regimen. The VAD regimen consisted of vincris-
tine 0·4 mg and doxorubicin 9 mg/m2, both administered in
100 ml NaCl 0·9% by intravenous rapid infusion (30 min
each) for 4 consecutive days. Dexamethasone was given
orally at a dose of 40 mg on days 1–4, 9–12 and 17–20
during uneven cycles of VAD. The treatment cycles were
repeated at 4-week intervals. All patients received flucona-
zole 200 mg/d and trimethroprim sulphamethoxazole
960 mg twice daily as prophylaxis against infections. The
use of anti-emetic drugs was allowed. Treatment was given
in the outpatient clinic via a peripheral intravenous catheter.
Evaluation of response. The response to VAD was evaluated
by follow-up bone marrow samples and follow-up serum and
urine M-protein measurements 3–4 weeks after the last VAD
cycle. The response to VAD was determined according to the
criteria of the Eastern Cooperative Oncology Group (ECOG).
Partial response (PR) was defined as a 50% or more decrease
of M-protein in serum or urine or >50% reduction of bone
marrow infiltration (in non-secretory myeloma). Complete
response (CR) was defined as no M-protein measurable in
serum and 10 times concentrated urine by immunofixation
analysis and <5% plasma cells with no abnormal morphol-
ogy in bone marrow smears. These plasma cells had to be
polyclonal by immunofluorescence staining. The median
duration of response was not analysed because induction
treatment was directly followed by intensified treatment.
RESULTS
One hundred and thirty-nine patients received a total of 416
cycles of VAD. 117 patients received three cycles of VAD and
13 patients received four cycles. Nine patients received one
or two cycles because of early death (four), no response
(three) or progressive disease (two). In addition, 26 patients
received local radiotherapy just before or during the VAD
cycles because of local symptoms.
Ninety-three patients (67%) were responsive according to
the ECOG criteria (Table II). 86 patients (62%) achieved a
partial remission: 24 patients with stage IIA disease, 55 with
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Table I. Patient characteristics.
No. of patients 139
Age (years)
Median 53
Range 32–65
Sex (male/female) 86/53
M-component
Immunoglobulin G 73
Immunoglobulin A 40
Immunoglobulin D 3
Immunoglobulin M 1
Light-chain disease 18
Non-secretory myeloma 4
Stage
IIA 42
IIB 1
IIIA 89
IIIB 7
Performance status (W.H.O.)
0 46
1 64
2 17
3 8
Unknown 4
Table II. Response to VAD according to stage of disease.
Disease No.
stage patients CR PR NR ED PD
IIA 42 4 24 12 1 1
IIB 1 0 0 1 0 0
IIIA 89 3 55 25 4 2
IIIB 7 0 7 0 0 0
Total 139 7 86 38 5 3
CR: complete remission; PR: partial remission; NR: no response;
ED: early death; PD: progressive disease.
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stage IIIA and seven with stage IIIB disease. Seven patients
(5%) entered a complete remission: four patients with stage
IIA and three patients with stage IIIA disease. 38 patients
(27%) showed no response. Three patients were progressive.
The response of five patients was not evaluable because of
early death due to toxicity or concomitant disease.
After VAD, 34 patients (25%) had a better W.H.O.
performance status than before treatment. In all patients
with stage IIB and IIIB disease (median creatinine 269 mmol/l;
range 183–814 mmol/l), the renal function normalized. 119
of the 139 patients (86%) were able to proceed to high-dose
therapy.
In order to determine the toxicity of rapid intravenous
infusion of VAD, the W.H.O. toxicity >2 was recorded during
all 416 VAD cycles (Table III). Significant nausea and
vomiting arose in nine cycles (2%). In 10 cycles (2%) patients
developed mucositis grade 2 or 3. Liver toxicity maximum
grade 3 was seen during eight cycles (2%), and in six cycles
(1%) mild to moderate renal function disturbances devel-
oped. One patient developed severe renal insufficiency.
Overall, neurotoxicity was present in 30/139 patients
(22%). Six patients developed neurotoxicity W.H.O. grade 1
(4%), 12 patients neurotoxicity W.H.O. grade 2 (9%) and 12
patients neurotoxicity W.H.O. grade 3 (9%). One patient had
cardiac dysrhythmias and one patient had a myocardial
infarction. No phlebitis was seen. In two patients cutaneous
toxicity W.H.O. grade 2 occurred due to extravasation.
Forty-two infection episodes W.H.O. grade >2 were reported
in 37 patients (27%). Five patients had an infection during two
cycles of VAD. Pulmonary infections were most common
occurring in 14 episodes. Documented bacteraemia was
observed in seven episodes. There were six cases of bacteraemia
caused by Gram-positive micro-organisms and one case with a
Gram-negative bacteraemia. 31 episodes required oral anti-
biotics and 11 episodes intravenous antibiotics.
Five patients died during VAD treatment. One patient
developed plasma cell leukaemia and died of progressive
disease. Two patients died of septic shock with acute
tubulus necrosis in one patient. One patient died of
respiratory insufficiency due to cardiac insufficiency. One
patient died of congestive heart failure following myocardial
infarction.
DISCUSSION
The VAD regimen was first used in patients with multiple
myeloma refractory to alkylating agents by Barlogie et al
(1984). In successive studies VAD was used as first-line
treatment in previously untreated myeloma patients or as
remission induction treatment prior to high-dose therapy
and autologous bone marrow transplantation (Alexanian
et al, 1990; Anderson et al, 1995; Attal et al, 1992;
Samson et al, 1989). The rationale of continuous VAD
regimen was based on the assumption that the addition of
corticosteroid pulses in high dosage improved the response
rate in patients with refractory myeloma and on in vitro
data which showed that a better tumour reduction was
achieved in myeloma cells by prolonged exposure when
compared to short exposure to vincristine (Alexanian et al,
1983, 1990; Barlogie et al, 1984; Drewinko et al, 1981;
Jackson et al, 1981). In addition, the peak serum
concentrations of vincristine and doxorubicin with VAD
administered as continuous infusion are low. This fact has
been regarded as a major reason why the risk of side-
effects such as polyneuropathy and cardiomyopathy is
relatively low, and an optimal anti-tumour effect is
maintained (Barlogie et al, 1984; Koskela et al, 1993);
however, it remains to be established if this results in a
better anti-tumour efficacy. In contrast to multiple
myeloma, in non-Hodgkin’s lymphoma it is attempted to
achieve a rapid response by rapid intravenous infusion of
the same agents in the CHOP regimen (Gottlieb et al,
1973).
A disadvantage of the administration of VAD as
continuous infusion is the necessity of a central venous
catheter, which makes outpatient administration difficult,
and it is associated with catheter-related problems such as
sepsis and thrombosis in 24% of the patients treated with
VAD as a remission induction therapy (Anderson et al,
1995).
In order to evaluate the feasibility and efficacy of VAD
application in a more convenient schedule we administered
vincristine and doxorubicin as a rapid intravenous infusion
in a large cohort of unselected patients. Potential advantages
of this approach were that no central venous catheter was
necessary during remission induction, that outpatient
administration was routinely possible, and that catheter-
related infections could be avoided. Thus, the insertion of
a central venous catheter could be delayed in patients
receiving an autologous stem cell transplantation. VAD was
chosen as a remission induction regimen prior to subsequent
intensive treatment because it induces rapid responses and is
not excessively myelosuppresive.
The response rate on remission induction treatment with
only three or four cycles of VAD administered as rapid
infusion was 67%. No direct comparison with continuous
infusion of VAD is possible because of the absence of
randomization for route of administration. Although this
study is not fully comparable with earlier studies with respect
to number of VAD cycles (six or seven courses versus three or
four courses in our study) and inclusion criteria (median age
53–57 years v 53 years in our study), it is known that
Table III. W.H.O. toxicity >2 during VAD
cycles.
No. of cycles
Nausea and vomiting 9 (2%)
Mucositis 10 (2%)
Liver 8 (2%)
Renal 7 (1%)
Cardiac 2 (0–1%)
No. of patients
Neurotoxicity 24 (18%)
Infections 37 (27%)
continuous infusion of VAD may result in a 55–84%
response rate in previously untreated patients (Alexanian
et al, 1990; Anderson et al, 1995; Samson et al, 1989). In
relapsed and refractory patients the response rate may vary
from 50% to 70% (Barlogie et al, 1984; Collin et al, 1987;
Lokhorst et al, 1989). Thus, rapid intravenous VAD (three or
four cycles) results in the same response rate as with
continuous infusion. From the present study, no conclusions
can be drawn about survival of these patients, since they
continued with further treatment. However, the primary aim
in these patients was to obtain a rapid response and to clear
the clinical symptoms for which three or four cycles seem to
be sufficient.
Treatment with VAD is often associated with a high
incidence of bacterial infections, which are frequently
catheter-related and are facilitated by high-dose steroids.
The fact that a central venous catheter is not required for
rapid intravenous infusion of VAD and prophylactic anti-
biotics were administered may have contributed to the
significantly lower incidence of serious infections in our
study as compared with earlier studies (27% v 54% with
antibiotic prophylaxis and 60% without antibiotic prophy-
laxis) (Anderson et al, 1995; Samson et al, 1989). Mild to
moderate neuropathy also occurred less frequently than the
incidence described in patients treated with continuous
infusion of VAD (22% v 100%) (Alexanian et al, 1990;
Samson et al, 1989). In this study the upper limit of age was
65 years. However, elderly patients with multiple myeloma
are even more vulnerable to (bacterial) infections and
neurotoxicity. Therefore the use of this regimen may also
benefit patients >65 years of age.
We conclude that VAD administered as a rapid intra-
venous infusion is as effective as continuous infusion for
remission treatment in previously untreated multiple mye-
loma. The most notable toxicities associated with VAD, i.e.
serious infections and neurotoxicity, had a significantly
lower incidence with this regimen. Therefore it can be
recommended for convenient outpatient administration in
stage II and III multiple myeloma.
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